Palvella Therapeutics (NASDAQ:PVLA) Receives $43.20 Consensus Price Target from Brokerages

Shares of Palvella Therapeutics (NASDAQ:PVLA) have earned a consensus recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $43.50.

Several analysts recently issued reports on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Scotiabank began coverage on Palvella Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target on the stock. Jones Trading assumed coverage on Palvella Therapeutics in a research report on Tuesday. They set a “buy” rating and a $45.00 price objective for the company. TD Cowen began coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price on the stock. Finally, Stifel Nicolaus began coverage on shares of Palvella Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $45.00 price target on the stock.

Palvella Therapeutics Price Performance

Shares of Palvella Therapeutics stock opened at $27.76 on Tuesday. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $29.27. The firm has a market capitalization of $311.49 million, a P/E ratio of -2.29 and a beta of 0.54. The business’s 50-day moving average price is $19.95.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in Palvella Therapeutics during the 4th quarter worth approximately $125,000. Toronto Dominion Bank bought a new position in shares of Palvella Therapeutics during the fourth quarter valued at $159,000. Geode Capital Management LLC bought a new position in shares of Palvella Therapeutics during the fourth quarter valued at $171,000. Cresset Asset Management LLC acquired a new position in shares of Palvella Therapeutics during the fourth quarter worth $251,000. Finally, Renaissance Technologies LLC acquired a new stake in Palvella Therapeutics in the fourth quarter valued at $256,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.